抗VEGF治疗的糖尿病黄斑水肿眼失访后的结局
这项单中心回顾性队列研究纳入90眼(73例)非增殖期糖尿病视网膜病变合并糖尿病黄斑水肿且接受抗VEGF注射后失访超过6个月的患者,评估失访对视觉和中心凹厚度的影响。
要点
- 按失访前NPDR严重程度分析,从失访前到最终随访视力无差异。
核心结论
- 抗VEGF治疗的DME患者长期失访后出现轻度视力下降,重新开始治疗后可恢复。
研究设计与样本
- 单中心回顾性队列研究,纳入90眼(73例)非增殖期糖尿病视网膜病变合并DME接受抗VEGF注射且失访超过6个月的患者。
主要发现
- 平均年龄64.5岁,平均失访时长322天,返回后平均随访502天。
- 返回后3个月(0.50,Snellen约20/63)、6个月(0.46,Snellen约20/57)、12个月(0.42,Snellen约20/52)及最终随访(0.47,Snellen约20/59)平均视力无显著变化。
- 按失访前NPDR严重程度分析,从失访前到最终随访视力无差异。
临床怎么用
- 对接受抗VEGF治疗的DME患者应强调规律随访,失访后返回时视力可能下降但 restart 治疗后可恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effect of loss to follow-up (LTFU) on outcomes in eyes with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (VEGF). DESIGN: Retrospective cohort study. METHODS: Single-center study of 90 eyes of 73 patients with nonproliferative diabetic retinopathy (NPDR) and DME treated with anti-VEGF injections who were LTFU for >6 months. Main outcomes were the change in mean visual acuity (VA) and central foveal thickness at the return and final visits compared with the visit before LTFU. RESULTS: The mean age was 64.5 years, the mean LTFU duration was 322 days, and the mean follow-up duration after return was 502 days. Compared with the mean VA at the visit before LTFU (0.42, Snellen ∼20/52), mean VA worsened at the return visit (0.54, Snellen ∼20/69, P = .004). No significant change in the mean VA was noted at the 3-month after return visit (0.50, Snellen ∼20/63), the 6-month after return visit (0.46, Snellen ∼20/57), the 12-month after return visit (0.42, Snellen ∼20/52), or the final follow-up (0.47, Snellen ∼20/59). When analyzed by NPDR severity before LTFU, no difference in VA was found from the visit before LTFU to the final visit. Mean central foveal thickness increased when comparing the visit before LTFU (270 μm) with the return visit (305 μm, P = .012), but no difference was found by the final visit (247 μm, P = .07). CONCLUSIONS: Anti-VEGF-treated patients with DME who were LTFU for a prolonged period experienced a modest decline in VA that recovered after restarting treatment.
引用
- Matsunaga DR, Salabati M, Obeid A, et al. Outcomes of Eyes With Diabetic Macular Edema That Are Lost to Follow-up After Anti-Vascular Endothelial Growth Factor Therapy. Am J Ophthalmol. 2021. PMID: 34283979. doi:10.1016/j.ajo.2021.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。